<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Development of institutional guidelines for use of high-cost biotechnology drugs, such as antithrombin III, is a valuable tool in formulary management </plain></SENT>
<SENT sid="1" pm="."><plain>This article describes the process by which the University of California Davis Medical Center used an ad hoc committee to the P &amp; T Committee to develop guidelines for antithrombin III use </plain></SENT>
<SENT sid="2" pm="."><plain>Performing an objective analysis of available literature to address the appropriate role of a biotechnology agent is necessary to develop consensus guidelines </plain></SENT>
<SENT sid="3" pm="."><plain>Approval of use guidelines by the P &amp; T Committee provides the necessary structure for optimal use of biotechnology agents, such as antithrombin III </plain></SENT>
</text></document>